HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bojestig, M. Articles by Nystrom, F. H. Search for Related Content PubMed PubMed Citation Articles by Bojestig, M. Articles by Nystrom, F. H. Social Bookmarking                What's this?

Reduction of ACE Activity Is Insufficient to Decrease Microalbuminuria in Normotensive Patients With Type 1 Diabetes

Department of Medicine and Care, University Hospital of Linköping, Linköping, Sweden

OBJECTIVE—To study whether administration of 1.25 and 5.0 mg ramipril daily, compared with placebo treatment, reduces the urinary albumin excretion rate (UAER) in normotensive patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS—Ramipril was administered double blind at two different doses (1.25 [n = 19] and 5.0 mg [n = 18]), and compared with placebo (n = 18) after a single-blind placebo period of 1–4 weeks. The patients (total, n = 55; women, n = 14) were followed for 2 years. To document an effect on the renin-angiotensin system, ACE activity and plasma-renin activity (PRA) were measured. In addition, 24-h ambulatory blood pressure (BP) was recorded at baseline and repeated after 1 and 2 years using a Spacelab 90207 ambulatory BP recording device (Spacelab, Redmont, CA).

RESULTS—Both doses of ramipril were sufficient to reduce ACE activity and to increase PRA significantly as compared with placebo (P < 0.05 for both). On the other hand, neither ambulatory nor clinic BP was affected by either dose of ramipril compared with the placebo group. There was no progression of UAER in the placebo group during the 2 years of the study. Analysis of covariance showed no differences in UAER between the three treatment groups at year 1 (P = 0.94) or year 2 (P = 0.97), after adjusting for baseline. Furthermore, there were no statistically significant changes from baseline UAER within any of the three treatment groups.

CONCLUSIONS—Treatment with ramipril did not affect microalbuminuria or clinic or ambulatory BP in this study. On the basis of the present study, we question the clinical use of ACE inhibitors in stably normotensive patients with type 1 diabetes and microalbuminuria in whom a concomitant reduction in BP is not demonstrated.

Abbreviations: ABP, ambulatory blood pressure • ACE, angiotensin I–converting enzyme • BP, blood pressure • GFR, glomerular filtration rate • PRA, plasma-renin activity • UAER, urinary albumin excretion rate

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Marre, M. Lievre, G. Chatellier, J. F E Mann, P. Passa, and J. Menard Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ, February 28, 2004; 328(7438): 495. [Abstract] [Full Text] [PDF]

				L. Poulsen Review: Early renal involvement in Type 1 diabetes mellitus -- Part 2: ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 17 - 26. [Abstract] [PDF]

				H.-H. Parving, N. Chaturvedi, G. Viberti, and C. E. Mogensen Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, February 1, 2002; 25(2): 406 - 407. [Full Text]